Long Term Safety and Efficacy Study of Tanezumab in Japanese Adult Subjects With Chronic Low Back Pain

NCT02725411

Last updated date
Study Location
Meitoh Hospital
Nagoya, Aichi, 465-0025, Japan
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Low Back Pain
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Duration of chronic low back pain for ≥3 months, and treatment with agents for low back pain for ≥3 months.

- Primary location of low back pain must be between the 12th thoracic vertebra and the lower gluteal folds, with or without radiation into the posterior thigh, classified as Category 1 or 2 according to the classification of the Quebec Task Force in Spinal Disorders.

- Subjects must be experiencing some benefits from their current stable dose regimen of oral NSAID (celecoxib, loxoprofen or meloxicam) treatment as described in the protocol, be tolerating their NSAID regimen, be taking this medication regularly during the 30 day period prior to the Screening visit and must have had some improvement in low back pain, but still require additional pain relief at Screening.

- Subjects must maintain a stabilized, protocol specified NSAID dose regimen for at least the final 2 or 3 weeks of the Screening period.

- Low Back Pain Intensity (LBPI) score of ≥5 at Screening.

- Subjects must be willing to discontinue all pain medications for chronic low back pain except rescue medication and investigational product and not use prohibited pain medications throughout the duration of the study.

- Female subjects of childbearing potential and at risk for pregnancy must agree to comply with protocol specified contraceptive requirements.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Subjects exceeding protocol defined BMI limits.


- Diagnosis of osteoarthritis of the knee or hip as defined by the ACR combined clinical
and radiographic criteria.


- Subjects who have Kellgren Lawrence Grade > or =2 radiographic evidence of hip or
Grade > or =3 radiographic evidence of knee osteoarthritis will be excluded.


- Subjects who have Kellgren Lawrence Grade < or =2 radiographic evidence of knee
osteoarthritis but who do not meet ACR criteria and do not have pain associated
with their knee osteoarthritis will be allowed.


- Subjects with symptoms and radiologic findings consistent with osteoarthritis in the
shoulder.


- History of lumbosacral radiculopathy within the past 2 years, history of spinal
stenosis associated with neurological impairment, or history of neurogenic
claudication.


- Back pain due to recent major trauma within 6 months prior to Screening.


- Surgical intervention during the past 6 months for the treatment of low back pain.


- Planned surgical procedure during the duration of the study.


- History or radiographic evidence of other diseases that could confound efficacy or
safety assessments (eg, rheumatoid arthritis).


- History or radiographic evidence of orthopedic conditions that may increase the risk
of, or confound assessment of joint safety conditions during the study.


- History of osteonecrosis or osteoporotic fracture.


- History of significant trauma or surgery to a knee, hip, or shoulder within the
previous year.


- Signs or symptoms of carpal tunnel syndrome in the one year prior to Screening.


- Considered unfit for surgery based upon American Society of Anesthesiologists physical
classification system for surgery grading, or subjects who would not be willing to
undergo joint replacement surgery if required.


- History of intolerance or hypersensitivity to celecoxib/acetaminophen or any of its
excipients or existence of a medical condition or use of concomitant medication for
which the use of celecoxib/acetaminophen is contraindicated.


- Use of prohibited medications or prohibited non-pharmacological treatments without the
appropriate washout period (if applicable) prior to Screening or IPAP.


- History of known alcohol, analgesic or narcotic abuse within 2 years of Screening.


- Presence of drugs of abuse or illegal drugs in the urine toxicology screen obtained at
Screening.


- History of allergic or anaphylactic reaction to a therapeutic or diagnostic monoclonal
antibody or IgG-fusion protein.


- Signs and symptoms of clinically significant cardiac disease.


- Poorly controlled hypertension as defined in the protocol or taking an
antihypertensive that has not been stable for at least 1 month prior to Screening.


- Evidence of protocol defined orthostatic hypotension at Screening.


- Disqualifying score on the Survey of Autonomic Symptoms questionnaire at Screening.


- Diagnosis of a transient ischemic attack in the 6 months prior to Screening, diagnosis
of stroke with residual deficits that would preclude completion of required study
activities.


- History of cancer within 5 years prior to Screening, except for cutaneous basal cell
or squamous cell cancer resolved by excision.


- Expected to undergo a therapeutic procedure or to use any analgesic other than those
specified in the protocol throughout the pre-treatment and treatment periods that is
likely to confound assessment of analgesic efficacy or safety.


- Previous exposure to exogenous NGF or to an anti-NGF antibody.


- Screening AST, ALT, serum creatinine or HbA1c values that exceed protocol defined
limits.


- Positive Hepatitis B, Hepatitis C, or HIV tests at screening indicative of current
infection.


- History, diagnosis, or signs and symptoms of clinically significant neurological
disease or clinically significant psychiatric disorder.


- Pregnant, breastfeeding or female subjects of childbearing potential who are unwilling
or unable to follow protocol required contraceptive requirements.


- Participation in other investigational drug studies within protocol defined time
limits.


- Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that in the judgment of the investigator, would make the subject
inappropriate for entry into this study.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Low Back PainComparison Of Celecoxib 200 Mg Bid, Loxoprofen Sodium 60 Mg Tid And Placebo In Low Back Pain In Japan
NCT00141154
  1. Funabashi-shi, Chiba
  2. Funabashi, Chiba
  3. Matsudo-shi, Chiba
  4. Fukuoka-shi, Fukuoka
  5. Chitose, Hokkaido
  6. Sapporo-shi, Hokkaido
  7. Sapporo, Hokkaido
  8. Katougun, Hyogo
  9. Kobe, Hyogo
  10. Nishinomiya, Hyogo
  11. Sagamihara-shi, Kanagawa
  12. Yokohama-shi, Kanagawa
  13. Yokohama, Kanagawa
  14. Hatogaya-shi, Saitama
  15. Kumagaya-shi, Saitama
  16. Kumagayashi, Saitama
  17. Minamisaitama-gun, Saitama
  18. Saitama-shi, Saitama
  19. Tokorozawa, Saitama
  20. Adachi-Ku, Tokyo
  21. Bunkyou-ku, Tokyo
  22. Edogawa-ku, Tokyo
  23. Itabashi-ku, Tokyo
  24. Koito-ku, Tokyo
  25. Meguro-Ku, Tokyo
  26. Nakano-ku, Tokyo
  27. Nerima-ku, Tokyo
  28. Ota-Ku, Tokyo
  29. Ota-Ku, Tokyo
  30. Setagaya-ku, Tokyo
  31. Shibuya-ku, Tokyo
  32. Shinagawa-ku, Tokyo
  33. Shinjyuku-ku, Tokyo
  34. Suginami-ku, Tokyo
  35. Sumida-ku, Tokyo
  36. Toyoshima-ku, Tokyo
  37. Chiba,
  38. Fukuoka,
  39. Fukuoka,
  40. Tokyo,
ALL GENDERS
20 Years+
years
MULTIPLE SITES
Low Back PainLong Term Safety Study of Tanezumab in Chronic Low Back Pain
NCT00924664
  1. Anniston, Alabama
  2. Hueytown, Alabama
  3. Huntsville, Alabama
  4. Mobile, Alabama
  5. Chandler, Arizona
  6. Peoria, Arizona
  7. Phoenix, Arizona
  8. Scottsdale, Arizona
  9. Tempe, Arizona
  10. Tempe, Arizona
  11. Little Rock, Arkansas
  12. Burbank, California
  13. Fresno, California
  14. Garden Grove, California
  15. La Jolla, California
  16. Los Gatos, California
  17. Oceanside, California
  18. Rancho Mirage, California
  19. Roseville, California
  20. Sacramento, California
  21. San Diego, California
  22. Upland, California
  23. Windomar, California
  24. Boulder, Colorado
  25. Colorado Springs, Colorado
  26. Stamford, Connecticut
  27. Trumbull, Connecticut
  28. Chiefland, Florida
  29. DeFuniak Springs, Florida
  30. DeLand, Florida
  31. Jacksonville, Florida
  32. Naples, Florida
  33. Orlando, Florida
  34. Pembroke Pines, Florida
  35. Pinellas Park, Florida
  36. South Miami, Florida
  37. St. Petersburg, Florida
  38. West Palm Beach, Florida
  39. Atlanta, Georgia
  40. Blue Ridge, Georgia
  41. Marietta, Georgia
  42. Boise, Idaho
  43. Evansville, Indiana
  44. Prairie Village, Kansas
  45. Topeka, Kansas
  46. Lexington, Kentucky
  47. Madisonville, Kentucky
  48. Monroe, Louisiana
  49. Baltimore, Maryland
  50. Worcester, Massachusetts
  51. Biloxi, Mississippi
  52. Jackson, Mississippi
  53. Springfield, Missouri
  54. St. Louis, Missouri
  55. St. Louis, Missouri
  56. Omaha, Nebraska
  57. Omaha, Nebraska
  58. Las Vegas,, Nevada
  59. Las Vegas, Nevada
  60. Berlin, New Jersey
  61. Willingboro, New Jersey
  62. Albuquerque, New Mexico
  63. Manlius, New York
  64. New York, New York
  65. New York, New York
  66. Rochester, New York
  67. Rochester, New York
  68. Williamsville, New York
  69. Greensboro, North Carolina
  70. Lenoir, North Carolina
  71. Raleigh, North Carolina
  72. Winston-Salem, North Carolina
  73. Cleveland, Ohio
  74. Oklahoma City, Oklahoma
  75. Oklahoma City, Oklahoma
  76. Medford, Oregon
  77. Portland, Oregon
  78. Altoona, Pennsylvania
  79. Bridgeville, Pennsylvania
  80. Duncansville, Pennsylvania
  81. Philadelphia, Pennsylvania
  82. Cranston, Rhode Island
  83. Warwick, Rhode Island
  84. Columbia, South Carolina
  85. Greer, South Carolina
  86. Rapid City, South Dakota
  87. Germantown, Tennessee
  88. Johnson City, Tennessee
  89. Austin, Texas
  90. Beaumont, Texas
  91. Beaumont, Texas
  92. Bryan, Texas
  93. Carroltown, Texas
  94. Dallas, Texas
  95. Houston, Texas
  96. Houston, Texas
  97. Houston, Texas
  98. Nassau Bay, Texas
  99. San Antonio, Texas
  100. Salt Lake City, Utah
  101. Salt Lake City, Utah
  102. Charlottesville, Virginia
  103. Norfolk, Virginia
  104. Richmond, Virginia
  105. Virginia Beach, Virginia
  106. Bellevue, Washington
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Low Back PainRandomized, Double Blind, Multicenter Study of the Safety and Efficacy of Valdecoxib 40 mg Once Daily Compared With Diclofenac 75 mg Twice Daily in Acute Low Back Pain
NCT00649610
  1. Bs. As.,
  2. Buenos Aires,
  3. Goiania, Goias
  4. Curitiba, Parana
  5. Curitiba, PR
  6. Petropolis, Rio de Janeiro
  7. Sao Paulo, SP
  8. Sao Paulo, SP
  9. Sao Paulo, SP
  10. Sao Paulo,
  11. Santiago,
  12. Bogota, D.c.
  13. Bogota D.c,
  14. Cali-valle,
  15. Cartago City, Cartago
  16. Hatillo, San Jose
  17. Quito, Pichincha
  18. Toluca, Edo. de Mexico
  19. Zapopan, Jalisco
  20. Zapopan, Jalisco
  21. Puebla,
  22. Puebla,
  23. Puebla,
  24. Lima,
  25. Lima,
  26. Caracas, DF
  27. Caracas, DF
  28. Caracas, DF
  29. Caracas,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Low Back PainA Study of Tanezumab in Adults With Chronic Low Back Pain
NCT00876187
  1. Anniston, Alabama
  2. Hueytown, Alabama
  3. Mobile, Alabama
  4. Chandler, Arizona
  5. Peoria, Arizona
  6. Phoenix, Arizona
  7. Phoenix, Arizona
  8. Scottsdale, Arizona
  9. Tempe, Arizona
  10. Tempe, Arizona
  11. Tucson, Arizona
  12. Little Rock, Arkansas
  13. Burbank, California
  14. Fresno, California
  15. Garden Grove, California
  16. La Jolla, California
  17. Los Gatos, California
  18. Oceanside, California
  19. Rancho Mirage, California
  20. Roseville, California
  21. Sacramento, California
  22. San Diego, California
  23. Upland, California
  24. Windomar, California
  25. Stamford, Connecticut
  26. Trumbull, Connecticut
  27. Chiefland, Florida
  28. DeFuniak Springs, Florida
  29. DeLand, Florida
  30. Fort Lauderdale, Florida
  31. Jacksonville, Florida
  32. Naples, Florida
  33. Orlando, Florida
  34. Pembroke Pines, Florida
  35. Pinellas Park, Florida
  36. South Miami, Florida
  37. St. Petersburg, Florida
  38. West Palm Beach, Florida
  39. Atlanta, Georgia
  40. Blue Ridge, Georgia
  41. Marietta, Georgia
  42. Boise, Idaho
  43. Evansville, Indiana
  44. Overland Park, Kansas
  45. Prairie Village, Kansas
  46. Topeka, Kansas
  47. Lexington, Kentucky
  48. Madisonville, Kentucky
  49. Monroe, Louisiana
  50. Baltimore, Maryland
  51. Worcester, Massachusetts
  52. Lansing, Michigan
  53. Biloxi, Mississippi
  54. Jackson, Mississippi
  55. St. Louis, Missouri
  56. Omaha, Nebraska
  57. Omaha, Nebraska
  58. Las Vagas, Nevada
  59. Las Vegas, Nevada
  60. Berlin, New Jersey
  61. Willingboro, New Jersey
  62. Albuquerque, New Mexico
  63. Manlius, New York
  64. New York, New York
  65. New York, New York
  66. Rochester, New York
  67. Rochester, New York
  68. Williamsville, New York
  69. Greensboro, North Carolina
  70. Lenoir, North Carolina
  71. Raleigh, North Carolina
  72. Winston-Salem, North Carolina
  73. Cincincinati, Ohio
  74. Cincinnati, Ohio
  75. Cleveland, Ohio
  76. Oklahoma City, Oklahoma
  77. Oklahoma City, Oklahoma
  78. Medford, Oregon
  79. Portland, Oregon
  80. Altoona, Pennsylvania
  81. Bethlehem, Pennsylvania
  82. Bridgeville, Pennsylvania
  83. Duncansville, Pennsylvania
  84. Philadelphia, Pennsylvania
  85. Cranston, Rhode Island
  86. Warwick, Rhode Island
  87. Columbia, South Carolina
  88. Greer, South Carolina
  89. Rapid City, South Dakota
  90. Germantown, Tennessee
  91. Johnson City, Tennessee
  92. Austin, Texas
  93. Austin, Texas
  94. Beaumont, Texas
  95. Bryan, Texas
  96. Carroltown, Texas
  97. Houston, Texas
  98. Houston, Texas
  99. Houston, Texas
  100. Houston, Texas
  101. Nassau Bay, Texas
  102. San Antonio, Texas
  103. San Antonio, Texas
  104. Salt Lake City, Utah
  105. Salt Lake City, Utah
  106. Charlottesville, Virginia
  107. Norfolk, Virginia
  108. Richmond, Virginia
  109. Virginia Beach, Virginia
  110. Bellevue, Washington
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Long Term Safety and Efficacy Study of Tanezumab in Japanese Adult Subjects With Chronic Low Back Pain
Official Title  ICMJE A PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER STUDY OF THE LONG-TERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN JAPANESE ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN
Brief Summary This study will investigate the long-term safety and efficacy of a fixed dose of tanezumab 5 mg and 10 mg administered subcutaneously (SC) seven times at 8 week intervals. The primary objective of this study is to evaluate the long term safety of tanezumab 5 mg and 10 mg administrated SC every 8 weeks (7 administrations). In addition, the study will evaluate the long term analgesic efficacy of tanezumab 5 mg and 10 mg SC administered every 8 weeks (7 administrations).
Detailed Description This is a randomized, double-blind, active-controlled, multicenter, parallel-group Phase 3 study of the safety and efficacy of tanezumab when administered by SC injection for up to 56 weeks in subjects with chronic low back pain. Subjects will be randomized to 1 of 3 treatment groups in a 1:1:1 ratio. Treatment groups will include: 1) Placebo SC matching tanezumab administered at an 8-week interval (total of 7 times) plus celecoxib 100 mg twice a day (BID) to be administered orally for 56 weeks; 2) Tanezumab 5 mg SC administered at an 8-week interval (total of 7 times) plus placebo matching celecoxib to be administered orally BID for 56 weeks; 3) Tanezumab 10 mg SC administered at an 8-week interval (total of 7 times) plus placebo matching celecoxib to be administered orally BID for 56 weeks. The study is designed with a total duration (post-randomization) of up to 80 weeks and will consist of three periods: Screening (up to 37 days; includes a Washout Period and an Initial Pain Assessment Period [IPAP]), a Double-blind Treatment Period (56 weeks) and a Follow-up Period (24 weeks). The Screening Period (beginning up to 37 days prior to Randomization) includes a Washout Period (lasting 2 to 32 days), if required, and an IPAP (the 5 days prior to Randomization/Baseline). Prior to entering the study, subjects must be experiencing some benefit (eg, analgesic effect) from their current stable dose regimen of oral NSAID (celecoxib, loxoprofen or meloxicam) treatment, be tolerating their NSAID regimen, be taking this medication regularly (defined as an average of at least 5 days per week) during the 30 day period prior to the Screening Visit.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Low Back Pain
Intervention  ICMJE
  • Drug: Celecoxib
    Orally administered Celecoxib 100 mg twice daily for 56 weeks
  • Biological: Tanezumab 5 mg
    Subcutaneous injection of tanezumab 5 mg every 8 weeks for 56 weeks
  • Biological: Tanezumab 10 mg
    Subcutaneous injection of tanezumab 10 mg every 8 weeks for 56 weeks
  • Drug: Placebo for celecoxib
    Orally administered the placebo twice daily for 56 weeks
  • Biological: Placebo for tanezumab
    Subcutaneous injection of the placebo every 8 weeks for 56 weeks
Study Arms  ICMJE
  • Active Comparator: Celecoxib
    Subcutaneous injection of placebo for tanezumab every 8 weeks plus oral celecoxib 100 mg twice daily for 56 weeks
    Interventions:
    • Drug: Celecoxib
    • Biological: Placebo for tanezumab
  • Experimental: Tanezumab 5 mg
    Subcutaneous injection of tanezumab 5 mg every 8 weeks plus oral placebo for celecoxib twice daily for 56 weeks
    Interventions:
    • Biological: Tanezumab 5 mg
    • Drug: Placebo for celecoxib
  • Experimental: Tanezumab 10 mg
    Subcutaneous injection of tanezumab 10 mg every 8 weeks plus oral placebo for celecoxib twice daily for 56 weeks
    Interventions:
    • Biological: Tanezumab 10 mg
    • Drug: Placebo for celecoxib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 5, 2018)
277
Original Estimated Enrollment  ICMJE
 (submitted: March 28, 2016)
390
Actual Study Completion Date  ICMJE June 2019
Actual Primary Completion Date June 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Duration of chronic low back pain for ?3 months, and treatment with agents for low back pain for ?3 months.
  • Primary location of low back pain must be between the 12th thoracic vertebra and the lower gluteal folds, with or without radiation into the posterior thigh, classified as Category 1 or 2 according to the classification of the Quebec Task Force in Spinal Disorders.
  • Subjects must be experiencing some benefits from their current stable dose regimen of oral NSAID (celecoxib, loxoprofen or meloxicam) treatment as described in the protocol, be tolerating their NSAID regimen, be taking this medication regularly during the 30 day period prior to the Screening visit and must have had some improvement in low back pain, but still require additional pain relief at Screening.
  • Subjects must maintain a stabilized, protocol specified NSAID dose regimen for at least the final 2 or 3 weeks of the Screening period.
  • Low Back Pain Intensity (LBPI) score of ?5 at Screening.
  • Subjects must be willing to discontinue all pain medications for chronic low back pain except rescue medication and investigational product and not use prohibited pain medications throughout the duration of the study.
  • Female subjects of childbearing potential and at risk for pregnancy must agree to comply with protocol specified contraceptive requirements.

Exclusion Criteria:

  • Subjects exceeding protocol defined BMI limits.
  • Diagnosis of osteoarthritis of the knee or hip as defined by the ACR combined clinical and radiographic criteria.

    • Subjects who have Kellgren Lawrence Grade > or =2 radiographic evidence of hip or Grade > or =3 radiographic evidence of knee osteoarthritis will be excluded.
    • Subjects who have Kellgren Lawrence Grade < or =2 radiographic evidence of knee osteoarthritis but who do not meet ACR criteria and do not have pain associated with their knee osteoarthritis will be allowed.
  • Subjects with symptoms and radiologic findings consistent with osteoarthritis in the shoulder.
  • History of lumbosacral radiculopathy within the past 2 years, history of spinal stenosis associated with neurological impairment, or history of neurogenic claudication.
  • Back pain due to recent major trauma within 6 months prior to Screening.
  • Surgical intervention during the past 6 months for the treatment of low back pain.
  • Planned surgical procedure during the duration of the study.
  • History or radiographic evidence of other diseases that could confound efficacy or safety assessments (eg, rheumatoid arthritis).
  • History or radiographic evidence of orthopedic conditions that may increase the risk of, or confound assessment of joint safety conditions during the study.
  • History of osteonecrosis or osteoporotic fracture.
  • History of significant trauma or surgery to a knee, hip, or shoulder within the previous year.
  • Signs or symptoms of carpal tunnel syndrome in the one year prior to Screening.
  • Considered unfit for surgery based upon American Society of Anesthesiologists physical classification system for surgery grading, or subjects who would not be willing to undergo joint replacement surgery if required.
  • History of intolerance or hypersensitivity to celecoxib/acetaminophen or any of its excipients or existence of a medical condition or use of concomitant medication for which the use of celecoxib/acetaminophen is contraindicated.
  • Use of prohibited medications or prohibited non-pharmacological treatments without the appropriate washout period (if applicable) prior to Screening or IPAP.
  • History of known alcohol, analgesic or narcotic abuse within 2 years of Screening.
  • Presence of drugs of abuse or illegal drugs in the urine toxicology screen obtained at Screening.
  • History of allergic or anaphylactic reaction to a therapeutic or diagnostic monoclonal antibody or IgG-fusion protein.
  • Signs and symptoms of clinically significant cardiac disease.
  • Poorly controlled hypertension as defined in the protocol or taking an antihypertensive that has not been stable for at least 1 month prior to Screening.
  • Evidence of protocol defined orthostatic hypotension at Screening.
  • Disqualifying score on the Survey of Autonomic Symptoms questionnaire at Screening.
  • Diagnosis of a transient ischemic attack in the 6 months prior to Screening, diagnosis of stroke with residual deficits that would preclude completion of required study activities.
  • History of cancer within 5 years prior to Screening, except for cutaneous basal cell or squamous cell cancer resolved by excision.
  • Expected to undergo a therapeutic procedure or to use any analgesic other than those specified in the protocol throughout the pre-treatment and treatment periods that is likely to confound assessment of analgesic efficacy or safety.
  • Previous exposure to exogenous NGF or to an anti-NGF antibody.
  • Screening AST, ALT, serum creatinine or HbA1c values that exceed protocol defined limits.
  • Positive Hepatitis B, Hepatitis C, or HIV tests at screening indicative of current infection.
  • History, diagnosis, or signs and symptoms of clinically significant neurological disease or clinically significant psychiatric disorder.
  • Pregnant, breastfeeding or female subjects of childbearing potential who are unwilling or unable to follow protocol required contraceptive requirements.
  • Participation in other investigational drug studies within protocol defined time limits.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that in the judgment of the investigator, would make the subject inappropriate for entry into this study.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Japan
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02725411
Other Study ID Numbers  ICMJE A4091063
JAPAN CLBP SC STUDY ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date July 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP